|
Miltenyi Biotec
cd45 viogreen Cd45 Viogreen, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody%2C+anti-human%2C+REAfinity/pm42985785-64-23-38 Average 96 stars, based on 1 article reviews
cd45 viogreen - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
anti cd45 microbeads Anti Cd45 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/CD45+MicroBeads%2C+mouse/pm43003077-839-185-187 Average 97 stars, based on 1 article reviews
anti cd45 microbeads - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
anti cd45 percp cy5 5 Anti Cd45 Percp Cy5 5, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/PerCP/pm43000390-109-6-7 Average 96 stars, based on 1 article reviews
anti cd45 percp cy5 5 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Novus Biologicals
dylight 650 conjugated anti cd45 ![]() Dylight 650 Conjugated Anti Cd45, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody+(30-F11)+-+BSA+Free/pmc13760287-47-30-37 Average 93 stars, based on 1 article reviews
dylight 650 conjugated anti cd45 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Novus Biologicals
anti mouse cd45 af 647 em 05 ![]() Anti Mouse Cd45 Af 647 Em 05, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody+(EM-05)+%5BAlexa+Fluor%C2%AE+647%5D/pm42982037-856-70-75 Average 94 stars, based on 1 article reviews
anti mouse cd45 af 647 em 05 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
anti cd45 2 ![]() Anti Cd45 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/CD45%2E2+Antibody%2C+anti-mouse/bio_rxiv__64898__2026__11__03__763975-67-27-28 Average 94 stars, based on 1 article reviews
anti cd45 2 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
rabbit monoclonal anti cd45 ![]() Rabbit Monoclonal Anti Cd45, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/CD45+Rabbit+mAb/pm42981186-194-238-241 Average 96 stars, based on 1 article reviews
rabbit monoclonal anti cd45 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
cd45 ![]() Cd45, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/PerCP+Anti-Human+CD45+Antibody/pmc13774206-48-21-23 Average 94 stars, based on 1 article reviews
cd45 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
antibodies against human cd45 ![]() Antibodies Against Human Cd45, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody%2C+anti-human%2C+REAfinity/bio_rxiv__64898__2026__11__02__763650-299-18-22 Average 96 stars, based on 1 article reviews
antibodies against human cd45 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Proteintech
coralite594 anti mouse cd45 antibody ![]() Coralite594 Anti Mouse Cd45 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+cd45+antibody/CD45+Antibody/pmc13755573-321-0-4 Average 96 stars, based on 1 article reviews
coralite594 anti mouse cd45 antibody - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
Journal: Investigative Ophthalmology & Visual Science
Article Title: Subconjunctival Injection of Anti-Secretogranin III Mitigates Corneal Damage in Alkali Burn Injury Model
doi: 10.1167/iovs.67.13.15
Figure Lengend Snippet: Therapeutic effects on inflammatory cell infiltration. ( A ) Representative OCT images of the anterior chamber 10 days post-alkali burn, including healthy, alkali burn only (untreated), and treatment with aflibercept or anti–Scg3 hAb, respectively. ( B ) H&E images showing leukocyte infiltration ( red arrows ) in the corneas, day 10 post-injury ( n = 3 corneas). ( C , D ) Images showing flow cytometry data ( C ) and quantification of CD45 + cells ( D ) on day 3 after alkali burn ( n = 3 samples per group; 5 corneas pooled per sample). ( E , F ) Immunofluorescence images of corneas stained with anti-CD45 ( E ), and the quantified number of CD45 + cells ( F ) ( n = 3 corneas). Scale bar : 50 µm. ( G , H ) Graphs showing mRNA expression of IL-1α ( G ) and TGF-β ( H ) ( n = 3 samples per group; 5 corneas pooled per sample). Data are presented as ±SEM. P < 0.05 (one-way ANOVA).
Article Snippet: The slides were then incubated with primary antibodies, including anti–fibronectin (ab2413, 1:500 dilution; Abcam, Cambridge, UK), anti–α-smooth muscle actin (α-SMA; SC56495, 1:500 dilution; Santa Cruz Biotechnology, Dallas, TX, USA), or
Techniques: Flow Cytometry, Immunofluorescence, Staining, Expressing
Journal: Frontiers in Pharmacology
Article Title: Anlotinib suppresses homologous recombination via the E2F8-RAD51 axis to activate STING immunity and potentiate PARP inhibitor synthetic lethality in resistant small cell lung cancer
doi: 10.3389/fphar.2026.1939827
Figure Lengend Snippet: Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Article Snippet: After treatment, MCTs were dissociated into single cells and stained with fluorescently labeled antibodies against CD8 (E-AB-F1109C, Elabscience), CD4 (E-AB-F1110E, Elabscience),
Techniques: Cell Function Assay, Western Blot, Analysis, Flow Cytometry
Journal: bioRxiv
Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES
doi: 10.64898/2026.11.02.763650
Figure Lengend Snippet: a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.
Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using
Techniques:
Journal: bioRxiv
Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES
doi: 10.64898/2026.11.02.763650
Figure Lengend Snippet: a. Relative viability of leukemic cells isolated from mice treated with a single intravenous dose of ASNase (100 IU/mouse) or vehicle (n = 3 mice per group). Cells were treated ex vivo with a two-fold serial dilution of ASNase (maximum concentration 2000 mIU/mL) for 72 h before viability was assessed using CellTiter-Glo. Concentrations were log-transformed. Each dot represents the mean of three biological replicates; error bars indicate SD. b. Relative ASNS mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. **p = 0.0038 (unpaired two-tailed t-test). c. Relative ATF4 mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. *p = 0.0238 (unpaired two-tailed t-test). d. Automated capillary western blot (WES) showing ASNS protein expression in leukemic cells isolated from mice in a treated with ASNase or vehicle. β-Actin serves as the loading control. Each lane is a biological replicate. e. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood. Mice received vehicle, ASNase (25 IU/mouse, single dose; n = 3), GCN2-IN-6 (3 mg/kg, oral dose every 3.5 days; n = 3), or the combination (n = 3). No significant differences were observed between treatment groups before treatment (day 0). At day 7, all treatment groups showed reduced leukemic burden compared with vehicle (*p = 0.0300 for ASNase, **p = 0.0017 for GCN2-IN-6, ***p = 0.0009 for the combination; one-way ANOVA with Dunnett’s multiple-comparison correction). Dots represent group means; error bars indicate SEM.
Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using
Techniques: Isolation, Ex Vivo, Serial Dilution, Concentration Assay, Transformation Assay, Expressing, Two Tailed Test, Automated, Western Blot, Control, Comparison
Journal: bioRxiv
Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES
doi: 10.64898/2026.11.02.763650
Figure Lengend Snippet: a-d. Leukemic burden, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood, in T-ALL PDX models 1–4 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. e-f. Leukemic burden, measured as the percentage of human CD19-positive (hCD19⁺) cells in peripheral blood, in B-ALL PDX models 1 and 2 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. g. Spleen weight of AML PDX-bearing mice treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Spleens were collected at the experimental endpoint. Statistical significance was determined using the Kruskal-Wallis test. **p = 0.0012. h. Leukemic burden, measured as the percentage of hCD45⁺ cells in peripheral blood, in the AML PDX model following treatment with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML) with time and treatment as fixed effects. *p = 0.0325. i. Relative tumor growth of an ovarian cancer cell line-derived xenograft (CDX) treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0008 j. Tumor volume of a neuroblastoma PDX treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 4 per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0002. k – n. Relative tumor growth of four TNBC PDX models treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 5 mice per group). Dots represent group means; error bars indicate SEM. Statistical analysis was performed using a linear mixed-effects model (REML). Significance is indicated in the figure.
Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using
Techniques: Analysis, Derivative Assay, Xenograft Assay
Journal: iScience
Article Title: In situ -activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy
doi: 10.1016/j.isci.2026.118090
Figure Lengend Snippet: The immune cells infiltration in TME of different therapy groups (A and B) Flow cytometry analysis and quantification of the percentage of M1-like macrophages in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ns, not significant; p > 0.05, ∗ p ≤ 0.05, ∗∗ p ≤ 0.01. (C and D) Flow cytometry analysis and quantification of the percentage of M2-like macrophages in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗ p ≤ 0.05. (E and F) Flow cytometry analysis and quantification of the percentage of mature DCs in tumors (gate out of CD11c + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. (G and H) Flow cytometry analysis and quantification of the percentage of CD8 + T cells in tumors (gate out of CD45 + cells, mean ± SEM, n = 3). p values were analyzed by one-way ANOVA, ∗∗∗∗ p ≤ 0.0001.
Article Snippet:
Techniques: Flow Cytometry, Analysis
Journal: iScience
Article Title: In situ -activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy
doi: 10.1016/j.isci.2026.118090
Figure Lengend Snippet:
Article Snippet:
Techniques: